CD19 and systemic lupus erythematosus: CD19/BCMA-Specific CAR-T: Dr. He Huang and colleagues reported the findings of a Phase I clinical trial in which 12 patients with refractory SLE were treated with CD19/BCMA CAR-T cells, according to data presented at the 2023 ASH meeting (https://ash.confex.com/ash/2023/webprogram/Paper186669.html).